Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Clinical Trials01:16

Clinical Trials

9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.5K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

8.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

medRxiv : the preprint server for health sciences·2026
Same author

Inhibition of chemokine CXCL12 modulates the tumor microenvironment in glioblastoma and potentiates immune checkpoint inhibitor efficacy in a tissue-specific manner.

Neuro-oncology advances·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.

Neuro-oncology advances·2026
Same author

Discovery of genetic susceptibility variants in pediatric and adult ependymoma.

Neuro-oncology advances·2026
Same journal

Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Spinal Cord Deformities Associated with Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Radiation Therapy for Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Treatment Strategies of Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Vascular Lesions of the Spinal Cord: Arteriovenous and Cavernous Malformations.

Neurosurgery clinics of North America·2026
Same journal

Hemangioblastomas of the Spinal Cord.

Neurosurgery clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Nov 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Molecularly Targeted Clinical Trials.

Matthew A Smith-Cohn1, Orieta Celiku2, Mark R Gilbert3

  • 1Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1016, Bethesda, MD 20892, USA; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Neurosurgery Clinics of North America
|March 30, 2021
PubMed
Summary
This summary is machine-generated.

Glioblastoma treatment faces challenges due to genetic diversity and the blood-brain barrier. Targeted synthetic lethality offers a promising new therapeutic avenue for glioblastoma patients.

Keywords:
Blood-brain barrierGlioblastomaHeterogenicitySynthetic lethalityTargeted therapy

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.1K

Related Experiment Videos

Last Updated: Nov 11, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.1K

Area of Science:

  • Neuro-oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Glioblastoma (GBM) remains a highly lethal brain cancer with limited treatment options.
  • Current therapies (surgery, radiation, chemotherapy) have shown minimal impact on overall survival.
  • Intrinsic tumor complexities like genetic heterogeneity and redundant pathways hinder treatment efficacy.

Purpose of the Study:

  • To review the challenges associated with molecularly targeted therapy in adult glioblastoma.
  • To explore the potential of synthetic lethality as a complementary therapeutic strategy.
  • To discuss current clinical trials and future directions for glioblastoma treatment.

Main Methods:

  • Literature review of glioblastoma molecularly targeted therapies.
  • Analysis of challenges including the blood-brain barrier and tumor heterogeneity.
  • Examination of synthetic lethality principles and their application to glioblastoma.

Main Results:

  • Molecularly targeted agents face significant hurdles in glioblastoma treatment.
  • Patient selection is crucial for therapeutic benefit, as indicated by subset responses.
  • Synthetic lethality presents a promising approach to overcome resistance mechanisms.

Conclusions:

  • Novel therapeutic strategies are urgently needed for glioblastoma.
  • Targeted synthetic lethality holds significant promise for improving glioblastoma outcomes.
  • Future research should focus on patient stratification and innovative therapeutic combinations.